• 1
    Gibson GE, Blass JP, Huang HM, Freeman GB. The cellular basis of delirium and its relevance to age-related disorders including Alzheimer's disease. Int. Psychogeriatr. 1991; 3: 373395.
  • 2
    Van Der Mast RC. Pathophysiology of delirium. J. Geriatr. Psychiatry Neurol. 1998; 11: 138145; 157–158.
  • 3
    Ross CA. CNS arousal systems: Possible role in delirium. Int. Psychogeriatr. 1991; 3: 353371.
  • 4
    Carpenter WT Jr. Serotonin-dopamine antagonists and treatment of negative symptoms. J. Clin. Psychopharmacol. 1995; 15: 30S35S.
  • 5
    APA. Practice guideline for the treatment of patients with delirium. Am. J. Psychiatry 1999; 156: 120.
  • 6
    Shapiro BA, Warren J, Egol AB et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: An executive summary. Society of Critical Care Medicine. Crit. Care Med. 1995; 23: 15961600.
  • 7
    Someya T, Endo T, Hara T, Yagi G, Suzuki J. A survey on the drug therapy for delirium. Psychiatry Clin. Neurosci. 2001; 55: 397401.
  • 8
    Casey DE. Acute extrapyramidal syndrome. In: ShriquiCLNH (ed.). Contemporary Use in the Treatement of Schizophrenia. American Psychiatric Press, Washington, DC, 1995; 535550.
  • 9
    Sipahimalani A, Masand PS. Use of risperidone in delirium: Case reports. Ann. Clin. Psychiatry 1997; 9: 105107.
  • 10
    Mittal D, Jimerson NA, Neely EP et al. Risperidone in the treatment of delirium: Results from a prospective open-label trial. J. Clin. Psychiatry 2004; 65: 662667.
  • 11
    Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 1998; 39: 422430.
  • 12
    Kim KS, Pae CU, Chae JH, Bahk WM, Jun T. An open pilot trial of olanzapine for delirium in the Korean population. Psychiatry Clin. Neurosci. 2001; 55: 515519.
  • 13
    Ravona-Springer R, Dolberg OT, Hirschmann S, Grunhaus L. Delirium in elderly patients treated with risperidone: A report of three cases. J. Clin. Psychopharmacol. 1998; 18: 171172.
  • 14
    Torres R, Mittal D, Kennedy R. Use of quetiapine in delirium: case reports. Psychosomatics 2001; 42: 347349.
  • 15
    Pae CU, Lee SJ, Lee CU, Lee C, Paik IH. A pilot trial of quetiapine for the treatment of patients with delirium. Hum. Psychopharmacol. 2004; 19: 125127.
  • 16
    Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45: 297301.
  • 17
    Giros B, El Mestikawy S, Godinot N et al. Cloning, pharmacological characterization, and chromosome as-signment of the human dopamine transporter. Mol. Pharmacol. 1992; 42: 383390.
  • 18
    Jaber M, Jones S, Giros B, Caron MG. The dopamine transporter: A crucial component regulating dopamine transmission. Mov. Disord. 1997; 12: 629633.
  • 19
    Nakamura Y, Koyama K, Matsushima M. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J. Hum. Genet. 1998; 43: 149152.
  • 20
    Fiskerstrand CE, Lovejoy EA, Quinn JP. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 1999; 458: 171174.
  • 21
    MacKenzie A, Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc. Natl Acad. Sci. USA 1999; 96: 15 251–15 255.
  • 22
    Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur. Neuropsychopharmacol. 2001; 11: 449455.
  • 23
    Inouye SK, Van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The confusion assessment method. A new method for detection of delirium. Ann. Intern. Med. 1990; 113: 941948.
  • 24
    Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: Comparison with the delirium rating scale and the cognitive test for delirium. J. Neuropsychiatry Clin. Neurosci. 2001; 13: 229242.
  • 25
    First MB, Gibbon M, Spitzer RL, Williams JBW. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorder (SCID-I), Clinical Version. American Psychiatric Press, Washington, DC, 1997.
  • 26
    American Psychiatry Assocation. Diagnostic and Statistical Manual of Psychiatric Disease (DSM-IV), 4th edn. American Psychiatric Press, Washington, DC, 1994.
  • 27
    Sano A, Kondoh K, Kakimoto Y, Kondo I. A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum. Genet. 1993; 91: 405406.
  • 28
    Sirois F. Delirium: 100 cases. Can. J. Psychiatry 1988; 33: 375378.
  • 29
    Breitbart W, Marotta R, Platt MM et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am. J. Psychiatry 1996; 153: 231237.
  • 30
    Nakamura J, Uchimura N, Yamada S, Nakazawa Y. [Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol]. Yakubutsu Seishin Kodo 1994; 14: 269277.
  • 31
    Platt MM, Breitbart W, Smith M, Marotta R, Weisman H, Jacobsen PB. Efficacy of neuroleptics for hypoactive delirium. J. Neuropsychiatry Clin. Neurosci. 1994; 6: 6667.
  • 32
    Pi EH. Transcultural psychopharmacology: Present and future. Psychiatry Clin. Neurosci. 1998; 52 (Suppl.): S185S187.
  • 33
    Pi EH, Wang AL, Gray GE. Asian/non-Asian transcultural tricyclic antidepressant psychopharmacology: A review. Prog. Neuropsychopharmacol. Biol. Psychiatry 1993; 17: 691702.
  • 34
    Breitbart W. Psycho-oncology: Depression, anxiety, delirium. Semin. Oncol. 1994; 21: 754769.
  • 35
    Liu CY, Juang YY, Liang HY, Lin NC, Yeh EK. Efficacy of risperidone in treating the hyperactive symptoms of delirium. Int. Clin. Psychopharmacol. 2004; 19: 165168.
  • 36
    Vandenbergh DJ, Persico AM, Uhl GR. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res. Mol. Brain Res. 1992; 15: 161166.
  • 37
    Mitchell RJ, Howlett S, Earl L et al. Distribution of the 3′ VNTR polymorphism in the human dopamine transporter gene in world populations. Hum. Biol. 2000; 72: 295304.
  • 38
    Nakatome M, Honda K, Islam MN et al. Amplification of DAT1 (human dopamine transporter gene) 3′ variable region in the Japanese population. Hum. Hered. 1995; 45: 262265.
  • 39
    Nakatome M, Honda K, Tun Z. et al. Genetic polymorphism of the 3′ VNTR region of the human dopaminergic function gene DAT1 (human dopamine transporter gene) in the Mongolian population. Hum. Biol. 1996; 68: 509515.